Clinical Trial Update: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study of 50561 in mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• 50561

Snippet

Sponsor: Beijing Joekai Biotechnology LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED